{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T19:42:28Z","timestamp":1773344548963,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jaip.2023.08.010","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T16:58:19Z","timestamp":1691686699000},"page":"3670-3679.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-Term Efficacy and Safety Among Patients With Severe Eosinophilic Asthma Treated With Mepolizumab and Its Effect on Small Airways"],"prefix":"10.1016","volume":"11","author":[{"given":"Ronald","family":"Strauss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Leflein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kolesar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Hammel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2023.08.010_bib1","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.08.010_bib2","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.jaci.2015.10.029","article-title":"Forced midexpiratory flow between 25% and 75% of forced vital capacity is associated with long-term persistence of asthma and poor asthma outcomes","volume":"137","author":"Siroux","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.08.010_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/23808993.2020.1776106","article-title":"Phenotyping severe asthma: a rationale for biologic therapy","volume":"5","author":"Vatrella","year":"2020","journal-title":"Exp Rev Precis Med Drug Dev"},{"key":"10.1016\/j.jaip.2023.08.010_bib4","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/j.jaip.2021.06.041","article-title":"Defining a severe asthma super-responder: findings from a Delphi process","volume":"9","author":"Upham","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.08.010_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jaip.2021.12.007","article-title":"Difficult-to-control asthma management in adults","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"J\u00a0Clin Allergy Immunol Pract"},{"key":"10.1016\/j.jaip.2023.08.010_bib6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S2213-2600(14)70103-1","article-title":"Unlocking the quiet zone: the small airway asthma phenotype","volume":"2","author":"Lipworth","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2023.08.010_bib7","article-title":"Small Airways: the \u201csilent zone\u201d of 2021 GINA Report?","volume":"9","author":"Cottini","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2023.08.010_bib8","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jaip.2019.10.040","article-title":"Clinical characterization and predictors of IOS-defined small-airway dysfunction in asthma","volume":"8","author":"Cottini","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.08.010_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145476","article-title":"Clinical implications of having reduced mid forced expiratory flow rates (FEF25\u201375), independently of FEV1, adult patients with asthma","volume":"10","author":"Riley","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2023.08.010_bib10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S2213-2600(19)30049-9","article-title":"Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study","volume":"7","author":"Postma","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2023.08.010_bib11","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00408-022-00579-2","article-title":"Impact of biologic therapy on the small airways asthma phenotype","volume":"200","author":"Chan","year":"2022","journal-title":"Lung"},{"key":"10.1016\/j.jaip.2023.08.010_bib12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000443797","article-title":"Association of FEF25-75% impairment with bronchial hyperresponsiveness and airway inflammation in subjects with asthma-like symptoms","volume":"91","author":"Malerba","year":"2016","journal-title":"Respiration"},{"key":"10.1016\/j.jaip.2023.08.010_bib13","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1016\/j.jaip.2021.06.027","article-title":"FEF25-75% is a more sensitive measure reflecting airway dysfunction in patients with asthma: a comparison study using FEF25-75% and FEV1","volume":"9","author":"Qin","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.08.010_bib14","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0091-6749(98)70252-0","article-title":"Cytokine mRNA expression in asthma is not restricted to the large airways","volume":"101","author":"Minshall","year":"1998","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.08.010_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.rmed.2019.01.016","article-title":"Mepolizumab improves small airway function in severe eosinophilic asthma","volume":"148","author":"Farah","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2023.08.010_bib16","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/biomedicines9111550","article-title":"Real-life effectiveness of mepolizumab on forced expiratory flow between 25% and 75% of forced vital capacity in patients with severe eosinophilic asthma","volume":"9","author":"Maglio","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jaip.2023.08.010_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2020.101899","article-title":"Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life","volume":"61","author":"Sposato","year":"2020","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaip.2023.08.010_bib18","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1159\/000520725","article-title":"Mepolizumab is an effective option in severe eosinophilic asthma regardless of baseline features: single-center real-life data","volume":"183","author":"Ozturk","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2023.08.010_bib19","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/02770903.2021.1897835","article-title":"Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study","volume":"59","author":"Enriquez-Rodriguez","year":"2022","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2023.08.010_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2020.101946","article-title":"Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma: Austrian real-life data","volume":"64","author":"Renner","year":"2020","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaip.2023.08.010_bib21","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1159\/000507996","article-title":"A\u00a0comprehensive evaluation of mepolizumab effectiveness in a real-life setting","volume":"181","author":"Cameli","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2023.08.010_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12890-018-0689-2","article-title":"Anti-IL-5 therapy in patients with severe eosinophilic asthma\u2014clinical efficacy and possible criteria for treatment response","volume":"18","author":"Drick","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaip.2023.08.010_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2020.100462","article-title":"Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities","volume":"13","author":"Crimi","year":"2020","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2023.08.010_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.08.010_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1034\/j.1399-3003.1999.14a06.x","article-title":"What are minimal important changes for asthma measures in a clinical trial?","volume":"14","author":"Santanello","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.08.010_bib26","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.08.010_bib27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.08.010_bib28","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.08.010_bib29","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.08.010_bib30","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2023.08.010_bib31","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2147\/DDDT.S150656","article-title":"Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the\u00a0therapeutic action of mepolizumab","volume":"11","author":"Pelaia","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jaip.2023.08.010_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.14425","article-title":"EAACI Biologicals Guidelines\u2014recommendations for severe asthma","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.08.010_bib33","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.clinthera.2019.07.007","article-title":"Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study","volume":"41","author":"Khurana","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaip.2023.08.010_bib34","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.jaip.2023.01.021","article-title":"Super-responders to biological treatment in type 2 high severe asthma: passing fad or meaningful phenotype?","volume":"11","author":"Portacci","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.08.010_bib35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \u201csuper-responder\u201d to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2023.08.010_bib36","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-term therapy response to anti-IL-5 biologics in severe asthma\u2014a real-life evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.08.010_bib37","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12931-020-01543-5","article-title":"Small airway dysfunction as a predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study","volume":"21","author":"Abdo","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2023.08.010_bib38","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1016\/j.jaip.2021.01.029","article-title":"Real-life small airway outcomes in severe asthma patients receiving biologic therapies","volume":"9","author":"Chan","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823009108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823009108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T05:21:56Z","timestamp":1716441716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219823009108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2213219823009108"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2023.08.010","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Efficacy and Safety Among Patients With Severe Eosinophilic Asthma Treated With Mepolizumab and Its Effect on Small Airways","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2023.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}